drugset / Trial / NCT02434822

A Study of Two Doses of Oral Cholera Vaccine (Shanchol™) in Subjects Aged 1 Year and Older in Dominican Republic

NCT02434822

Phase 3 Completed 336 enrolled Sanofi Pasteur, a Sanofi Company
Non-randomizedParallel-groupOpen-labelPrevention

Summary

The aim of the study is to generate safety and immunogenicity data with Shanchol in The Philippines Objectives: * To describe the safety after each dose of Shanchol vaccine. * To describe the immunogenicity after each dose of Shanchol vaccine.

Timeline

Start
2015-04
Primary completion
2015-09
Completion
2016-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Shanchol Vaccine 1.5 ml Oral

Indications